Leading law firm, MinterEllison, has acted on three acquisitions by DBG Health valued at over $1 billion, the newly formed pharmaceutical company majority controlled by Dennis Bastas.

DBG Health has acquired all outstanding shares in Arrotex Pharmaceuticals, buying out the 50% shareholding previously held by the Sherman family and purchasing Juno Pharmaceuticals. Additionally, DBG Health has secured the pharmaceutical consulting business, Axe Health.

The MinterEllison M&A team, led by partner Jeremy Blackshaw advised on all transactions.

Arrotex Pharmaceuticals, Australia’s largest generic pharmaceutical and private-label over-the-counter medicines company, holds a substantial market share of the generic pharmacy market, including the Chemists Own brand, with 300 generic and branded products across a range of categories, including
for the treatment of digestion, colds and flu, hayfever and other allergies.

Juno Pharmaceuticals, a privately held company based in Victoria, specialises in marketing and distribution services for pharmaceutical manufacturers, with a focus on generic pharmaceutical products.

Mr Bastas & Arrotex are long standing clients of MinterEllison. The firm has consistently supported the group’s growth, having previously advised on transactions such as Arrotex Investments’ acquisition of Arrotex Holdings and Arrotex Pharmaceutical’s acquisition of Farmaforce.

Jeremy Blackshaw commented, “We are delighted to have advised on these recent acquisitions as DBG Health & the Arrotex group continues to strengthen and expand. This latest work demonstrates our leading M&A expertise and deep knowledge of the health and pharmaceutical sector.”